Fig 1.
Enrollment flow chart of patients.
Table 1.
Clinical characteristics according to metabolic syndrome [46].
Table 2.
Clinical characteristics according to obesity, visceral adiposity, and sarcopenia [46].
Fig 2.
(A) The prevalence of MS in subjects with obesity, visceral adiposity, or sarcopenia was higher than that in subjects without these parameters (P < 0.001 for all). (B) The prevalence of severe MS in subjects with obesity, visceral adiposity, or sarcopenia was higher than that in subjects without them (P < 0.001 for all). MS, metabolic syndrome.
Table 3.
Comparisons of number of metabolic parameters according to obesity, visceral adiposity, or sarcopenia.
Table 4.
Descriptive numerical values of body mass index, visceral fat area, and ASM% according to the number of metabolic parameters.
Fig 3.
(A) The number of metabolic parameters according to the number of unfavorable body composition parameters (obesity, visceral adiposity, and sarcopenia). (B) The prevalence of MS according to the number of unfavorable body composition parameters (obesity, visceral adiposity, and sarcopenia). (P for trend < 0.001 in all); MS, metabolic syndrome.
Fig 4.
The prevalence of MS in paired analyses according to (A) obesity and visceral adiposity, (B) obesity and sarcopenia, and (C) visceral adiposity and sarcopenia; MS, metabolic syndrome.
Table 5.
Odds ratios of metabolic syndrome according to the presence of obesity, visceral adiposity, and sarcopenia.
Fig 5.
(A) Correlation of VFA measured by Inbody 720 and CT scan (R = 0.743, P<0.001), (B) Correlation of ASM measured by Inbody 720 and TAMA at the L3 vertebral level measured by CT scan (R = 0.890, P < 0.001) [46]. VFA, visceral fat area; CT, computed tomography; ASM, appendicular skeletal muscle mass; TAMA, total abdominal muscle area.